Browse >
Home /
Vyvanse News / FDA approves sNDA for pediatric autism drug ABILIFY (News-Medical-Net)
FDA approves sNDA for pediatric autism drug ABILIFY (News-Medical-Net)
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self ...
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with 17 Years, Abilify, Aggression, Aripiprazole, Autism, Autistic Disorder, Bristol Myers, Bristol Myers Squibb, Bristol Myers Squibb Company, Drug Application, Fda, Fda Approved, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Irritability, Myers Squibb Company, Otsuka Pharmaceutical Co, Pediatric Patients, Snda
